Scientific Advisory Board
Alejandro R. Ayala, M.D.
Dr. Alejandro Ayala obtained his MD from the Universidade Federal Fluminese in Rio de Janeiro, Brazil, in 1992, and completed his residency in internal medicine at the Federal University of Sao Paulo. He subsequently joined the Georgetown University Program in Internal Medicine at The Washington Hospital Center. Dr. Ayala obtained his clinical training in Endocrinology at Johns Hopkins University Hospital, followed by a research fellowship at the Clinical Neuroendocrinology Branch at the National Institutes of Health (NIH) in Bethesda , Maryland where he continued for the next five years as a staff clinician, clinical investigator and faculty of the NIH Endocrinology training program. He also served as an Associate Clinical Director at Wyeth/Pfizer, Collegeville, PA focusing on early drug development. Dr. Ayala obtained his MBA at the University of Miami where he currently serves as an Associate Professor of Clinical Medicine/Endocrinology and Director of the Neuroendocrine/Pituitary diseases program. His research interests are related to Neuroendocrinology, Hypogonadism, Pituitary, Hypothalamic and Adrenal Disorders, areas in which he has authored more than two dozen peer-reviewed articles and book chapters.
George G. Nomikos, MD, PhD. Cofounder
Dr. Nomikos has over 25 years of experience in both academia and industry in neuroscience research, drug discovery & development, neuropsychopharmacology, biological psychiatry and CNS therapeutics. He has contributed to the discovery and development of several CNS compounds from candidate identification to early and late clinical development and regulatory approval. Dr Nomikos has led large cross-organizational teams to key decision and advancement points in CNS research and drug discovery & development, and has served as a global clinical science director in early development and registration/pivotal clinical trials in neuropsychiatry, neurodegeneration and chronic pain.
Aldemar Degroot, MS, PhD. Cofounder
Dr. Degroot has approximately 15 years experience in international drug development, including licensing and commercial activities. Experience was gained across several therapeutic areas, with a focus on disorders that affect the central nervous system. Throughout his career, Dr. Degroot has identified, licensed, and overseen development of numerous drug candidates, ensuring and maximizing their commercial viability. In addition, he has been instrumental in managing development of drug candidates as they transition from preclinical to clinical development. He is further specialized in deal-making and negotiation in relation to licensing opportunities for drug candidates and novel technologies. Dr. Degroot participated in the submission and successful approval of multiple global submission documents. He obtained his experience in the United States, Canada, Europe, and Japan in both large and small pharmaceutical companies, including Astellas and Eli Lilly. Dr. Degroot received a MS in pharmacology and a PhD in neuropsychology, both from the University of Alberta.